Quick Answer
CUMBERLAND PHARMACEUTICALS INC reported Net Income Loss of -$2.84 million for the year ending 2025.
- CUMBERLAND PHARMACEUTICALS INC showed an increase of +56.2% in Net Income Loss from 2024 to 2025.
- This data is from CUMBERLAND PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), CUMBERLAND PHARMACEUTICALS INC's Net Income Loss has declined by 191.7%.
- Historical annual values: Fiscal year 2025: -$2.84 million | Fiscal year 2024: -$6.48 million | Fiscal year 2023: -$6.28 million | Fiscal year 2022: -$5.57 million | Fiscal year 2021: -$3.51 million | Fiscal year 2020: -$3.34 million | Fiscal year 2019: -$3.54 million | Fiscal year 2018: -$6.96 million | Fiscal year 2017: -$7.98 million | Fiscal year 2016: -$944.7 thousand | Fiscal year 2015: $731.4 thousand | Fiscal year 2014: $2.42 million | Fiscal year 2013: -$2.10 million | Fiscal year 2012: $5.84 million | Fiscal year 2011: $5.66 million | Fiscal year 2010: $2.46 million | Fiscal year 2009: $3.09 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: